Moderna (NASDAQ:MRNA) is up 1.8%
postmarket after getting a Street-high price target from BMO Capital
Markets, which started the stock with an Outperform rating.
That’s based on advancing its coronavirus vaccine candidate.
The firm’s set a price target of $83, implying 79% upside.
The success of the candidate isn’t certain, of
course, but BMO sees a high probability that Phase 1 results will show
the generation of neutralizing antibody titers when reported in June –
and a meaningful number of volunteers generating antibodies is a
near-term value driver.
Government funding and promising results from later-stage candidates help validate the potential, analyst George Farmer says.
https://seekingalpha.com/news/3566580-modernaplus-1_8-bmo-sets-street-high-target
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.